4.2.2.3Vertical
Medication-Assisted Treatment (MAT)
Programs using buprenorphine, methadone, or naltrexone for addiction treatment.
Market snapshot
These figures describe Addiction & Substance Use Treatment (4.2.2), the segment that Medication-Assisted Treatment (MAT) sits within. They are not figures for Medication-Assisted Treatment (MAT) on its own.
FragmentationConsolidatingEstimate
No single discrete Census NAICS code covers addiction treatment, which spans outpatient centers (621420), residential (623220), and hospitals (622210), so the segment is not separately sized by the Census Bureau.
Business model & economics
Revenue model
Per-diem residential, outpatient, and MAT reimbursement
Key economics
- Recurring revenue
- Moderate–High
- EBITDA margin
- 12–22%
- Capex intensity
- Moderate
recurring MAT and outpatient care
Characteristics
- Demand driven by the opioid and addiction crisis.
- MAT expanded evidence-based, recurring treatment.
- Fraught history of scandals and quality concerns.
M&A deal context
Deal activityHigh
Who’s acquiring
- PE-backed treatment platforms
- MAT and outpatient consolidators
- Behavioral-health operators
What’s driving deals
- Consolidation of treatment providers.
- Opioid-crisis and addiction demand.
- Regulatory and reputational scrutiny.
Find Medication-Assisted Treatment (MAT) acquisition targets
Search Acquisera’s index for companies classified under Medication-Assisted Treatment (MAT) (4.2.2.3) and build a targeted deal pipeline.
Search companies